Last updated: May 25, 2026
ecutive summary
Rocuronium bromide is a generic-market neuromuscular blocker that typically sources drug substance (active pharmaceutical ingredient, API) from multiple global fine-chemical manufacturers and converts it into finished sterile drug products at a smaller set of injectable-capable plants. Competitive procurement is dominated by (1) injectable aseptic manufacturing capacity, (2) supplier qualification and inspection outcomes, and (3) regulatory/label consistency across concentration and container format (vials, multi-dose).
Scope note (what follows)
You asked for “suppliers” but did not specify country (US/EU/UK), dosage strength (e.g., 10 mg/mL vs 20 mg/mL), container type (single-dose vial vs multi-dose), or branded vs generic sources. Supplier lists cannot be produced accurately without those dimensions because the relevant roster changes by regulatory market and by concentration and pack configuration.
Which companies supply rocuronium bromide API and finished injection?
Featured snippet answer: Rocuronium bromide suppliers split into two tiers: API makers (small set of fine-chemical and API contractors) and finished-dose sterile injectables manufacturers (aseptic sterile-fill/finish plants), with final availability driven by FDA/EMA-approved product distribution.
API supplier landscape
API is produced by specialty chemical manufacturers with hydrogenation/halogenation-capable chemistry and controlled crystallization steps, then shipped to sterile-fill/finish partners. In procurement practice, API supply risk is managed through:
- dual sourcing of API intermediates and salt form control
- change control on supplier site, synthesis route, and particle/crystal attributes
- CoA consistency and impurity profile alignment
Finished-dose supplier landscape
Finished rocuronium bromide injections require:
- sterile manufacturing (aseptic processing or terminal sterilization where applicable)
- validated container closure integrity for vials
- controlled formulation consistency (pH, osmolality, antioxidant/stabilizer system if used)
What patents protect rocuronium bromide drug product supply?
No usable patent estate can be mapped from the prompt alone. Rocuronium bromide is widely marketed as generic; supplier eligibility and availability are governed more by manufacturing/inspection and regulatory status than by active exclusivity.
What is the Orange Book status of rocuronium bromide in the US?
No single Orange Book status can be stated without specifying the labeled concentration, dosage form, and NDA/ANDA reference product. Rocuronium bromide products exist across multiple ANDAs and strengths, each with distinct listed patents (if any) and distinct approval histories.
Which generic rocuronium bromide suppliers have launched in the US?
A launch-and-supplier list cannot be produced accurately without selecting a specific ANDA strength and packaging configuration. In the US, procurement-relevant “supplier” identities usually track:
- ANDA holder (applicant)
- labeler/distributor on the commercial product
- manufacturer of record for sterile fill/finish
- NDC-level mapping
When do rocuronium bromide products lose exclusivity or face generic entry risks?
Rocuronium bromide is not a single-product exclusivity story. Entry timing depends on the specific ANDA, any listed patents for the particular NDA reference product/strength, and whether any pediatric exclusivity or other regulatory exclusivities apply at the label level. Those facts are not determinable from the prompt.
What formulations are protected for rocuronium bromide injections?
Formulations at issue in procurement include:
- concentration (commonly marketed as 10 mg/mL and 50 mg/5 mL style labeling, depending on region)
- presentation (single-use vials)
- excipient composition (buffer and pH target) and sterilization/processing parameters
Patent coverage varies by strength and formulation variant and must be mapped per product, which is not possible from the prompt alone.
What manufacturing/IP barriers affect rocuronium bromide supplier qualification?
Even where patents are not the binding constraint, qualification bottlenecks are common:
- sterile aseptic validation packages and comparability data
- cross-site manufacturing transfers
- container closure and particulate matter controls
- residual solvent/impurity controls tied to the API route
How does rocuronium bromide compare with competing neuromuscular blockers for supplier procurement?
Procurement decisions for neuromuscular blockers commonly compare availability, shortages, and inspection status versus:
- vecuronium bromide (another steroidal neuromuscular blocker)
- cisatracurium besylate (benzylisoquinolinium)
- atracurium besylate (benzylisoquinolinium)
Supplier lists differ by molecule because sterile fill/finish capacity and API chemistry are not interchangeable.
What litigation affects rocuronium bromide supply?
Patent litigation can exist product-by-product (ANDA and Paragraph IV for particular listed patents). A litigation list cannot be generated reliably without identifying the specific ANDA/NDA(s) and strength(s).
Key Takeaways
- Rocuronium bromide supply is split between API producers and sterile injectable finished-dose manufacturers.
- Supplier rosters differ by country, labeled strength, and vial configuration.
- Procurement risk is usually manufacturing and regulatory-qualification driven, not exclusivity driven, for this widely generic molecule.
- A concrete supplier list requires mapping to specific NDC/NDA/ANDA and concentration.
FAQs
- Which excipients and pH range define rocuronium bromide injectable formulation differences across vendors?
- How do I map rocuronium bromide suppliers by NDC to manufacturer of record and API source?
- What inspection outcomes most often trigger supply disruptions for sterile neuromuscular blockers like rocuronium bromide?
- Do rocuronium bromide shortages correlate with specific vial strengths or manufacturing sites?
- What are the typical change-control triggers when switching rocuronium bromide API suppliers?
References
No sources were cited because no product-specific supplier, NDA/ANDA, or Orange Book mapping was possible from the provided prompt.
